InflaRx rises on positive trial results from its anti-inflammatory drug

Inflarx NV

04/01/2024 13:47

** U.S.-listed shares of German-based biopharma company
InflaRx  IF0G.F   IFRX.O  rise 5.6% to $1.7 premarket
    ** Co's experimental inflammatory drug, INF904, was well
tolerated with no safety concerns in an early-stage study 
    ** The drug targets C5a receptor that modulates inflammatory
responses and obesity 
    ** Plans to advance INF904 to a mid-stage study towards the
end of 2024
     ** Co is also conducting additional pre-clinical studies to
enable longer-term dosing of drug for inflammatory diseases 
    ** Stock was down 47.4% in 2023, after hitting a near
two-year high after receiving FDA's emergency-use authorization
for its COVID injection

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))